{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250677","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.981625+00:00","generated_at":"2026-05-17T02:13:45.874259+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical","bullets":["Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.","NMRA-898 is structurally distinct from NMRA-861 (Phase 1 started July 2025); both may offer best-in-class pharmacology.","No convulsions observed in preclinical studies across multiple species, including rabbits.","Neumora expects to provide a comprehensive M4 franchise update by mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250677","json":"https://secwatch.observer/filing/0001193125-25-250677.json","markdown":"https://secwatch.observer/filing/0001193125-25-250677.md","text":"https://secwatch.observer/filing/0001193125-25-250677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/0001193125-25-250677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/nmra-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:13:45.874259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}